Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antagonists selective for estrogen receptor alpha.

Jun Sun1, Ying R Huang, William R Harrington

  • 1Department of Molecular and Integrative Physiology, University of Illinois and University of Illinois College of Medicine, Urbana, Illinois 61801, USA.

Endocrinology
|February 28, 2002
PubMed
Summary

Researchers developed novel basic side-chain pyrazoles (BSC-pyrazoles) that selectively block estrogen receptor alpha (ER(alpha)) activity, offering a targeted approach for studying ER(alpha) functions and developing new therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6.

NPJ breast cancer·2026
Same author

Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression.

Cancer letters·2025
Same author

Chloroindazole based estrogen receptor β ligands with favorable pharmacokinetics promote functional remyelination and visual recovery.

Scientific reports·2025
Same author

Benzestrol Isomer Stereochemistry Determines the Distinct Estrogenic Activities and Conformations of the Eight Isomers When Bound to Estrogen Receptor α.

ACS pharmacology & translational science·2025
Same author

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

FOXM1 targeting alters AURKB activity and reshapes antitumor immunity to curb the progression of small cell lung cancer.

Research square·2025

Area of Science:

  • Medicinal Chemistry
  • Endocrinology
  • Molecular Pharmacology

Background:

  • Estrogen receptors (ERs), specifically ER(alpha) and ER(beta), play critical roles in various physiological processes.
  • Selective modulation of ER subtypes is crucial for targeted therapeutic interventions.
  • Existing nonsteroidal antiestrogens often lack subtype selectivity, affecting both ER(alpha) and ER(beta).

Purpose of the Study:

  • To design and synthesize novel compounds that act as selective antagonists for ER(alpha) but not ER(beta).
  • To investigate the potency and selectivity of these novel compounds on different estrogen response elements and gene targets.
  • To evaluate the potential of these selective antagonists in understanding ER subtype-specific functions.

Main Methods:

  • Modification of pyrazole compounds with basic side-chains to enhance ER(alpha) affinity and selectivity.

Related Experiment Videos

  • Synthesis and characterization of seven distinct basic side-chain pyrazole (BSC-pyrazole) derivatives.
  • In vitro evaluation of antagonist activity on various reporter-promoter gene constructs and specific genes (pS2, TGF(beta)3) in the presence of estradiol (E2).
  • Comparison of BSC-pyrazoles' selectivity profile with established antiestrogens like trans-hydroxytamoxifen, raloxifene, and ICI 182,780.

    • Main Results:

    • Developed BSC-pyrazoles with high affinity and potent, selective antagonism on ER(alpha).
    • Identified methyl-piperidino-pyrazole (MPP) as the most ER(alpha)-selective compound among the tested derivatives.
    • Demonstrated ER(alpha)-selective antagonism across diverse estrogen response elements and indirect ER-mediated gene regulation.
    • MPP effectively antagonized E2-stimulated pS2 mRNA in MCF-7 cells, which predominantly express ER(alpha).

    Conclusions:

    • BSC-pyrazoles, particularly MPP, represent a new class of potent and selective ER(alpha) antagonists.
    • These compounds exhibit distinct selectivity profiles compared to current broad-acting antiestrogens.
    • The developed BSC-pyrazoles are valuable tools for dissecting the specific biological roles of ER(alpha) and ER(beta).
    • This research opens avenues for developing targeted therapies that selectively inhibit ER(alpha)-mediated responses.